How much funding has Inhibrx Biosciences raised?

Inhibrx Biosciences has raised $250.0M in total funding, most recently a Private Equity round.

Who are Inhibrx Biosciences's investors?

Inhibrx Biosciences's investors include RA Capital Management, Jefferies, Evercore ISI, Credit Suisse, Oxford Finance.

When was Inhibrx Biosciences founded?

Inhibrx Biosciences was founded in 2024.

Where is Inhibrx Biosciences headquartered?

Inhibrx Biosciences is headquartered in La Jolla, California, United States.

What industry is Inhibrx Biosciences in?

Inhibrx Biosciences operates in Biotech, Healthcare.

How many employees does Inhibrx Biosciences have?

Inhibrx Biosciences has 51-200 employees.

Inhibrx Biosciences

IPO

Inhibrx | Discover our clinical-stage biotechnology company.

Public · La Jolla, United States · Founded 2024 · $250.0M raised

Biotech

Healthcare

Headquarters: La Jolla, California
Employees: 51–200
Founded: 2024
Business Model: B2B
Website: inhibrx.com

Total Funding: $250.0M
Last Round: $200.0M Private EquityAug 2023
Rounds: 2
Type: Public

About

Inhibrx Biosciences is a clinical-stage biopharmaceutical company developing biologic therapeutics for people with life-threatening conditions. Leveraging deep protein engineering expertise, the company has two lead clinical programs — ozekibart (INBRX-109) in sarcoma and INBRX-106 in head and neck cancer. The team combines scientific rigor with the agility of a startup to advance novel immunotherapy candidates.

Summary

Inhibrx Biosciences is a Biotech company based in La Jolla, United States, founded in 2024. It has raised $250.0M in total across 2 rounds, most recently a $200.0M Private Equity round in Aug 2023. Investors include RA Capital Management, Jefferies and Evercore ISI.

LinkedIn X (Twitter)